Selected research
Industry Growth & Trends
Global Gastric Mucosal Protective Drug Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Gastric Mucosal Protective Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Gastric Mucosal Protective Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Gastric Mucosal Protective Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Gastric Mucosal Protective Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Gastric Mucosal Protective Drug market include Zhejaing Yuanlijian, Eisai Co., Teva, LIVZON, Guangdong Huanan Pharma, Bayer, AbbVie, Viatris and Otsuka Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Gastric Mucosal Protective Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Gastric Mucosal Protective Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Gastric Mucosal Protective Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Gastric Mucosal Protective Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Gastric Mucosal Protective Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Gastric Mucosal Protective Drug Market by Company
Zhejaing Yuanlijian
Eisai Co.
Teva
LIVZON
Guangdong Huanan Pharma
Bayer
AbbVie
Viatris
Otsuka Pharmaceutical
Nostrum Pharmaceuticals
Endo International
Astellas Pharma
Amneal Pharmaceuticals
Gastric Mucosal Protective Drug Segment by Type
Rebamipide
Sucralfate
Bismuth Potassium Citrate
Other
Gastric Mucosal Protective Drug Segment by Application
Hospital
Retail Pharmacy
Other
Gastric Mucosal Protective Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Mucosal Protective Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastric Mucosal Protective Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Mucosal Protective Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Gastric Mucosal Protective Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Rebamipide
- Sucralfate
- Bismuth Potassium Citrate
- Other
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Zhejaing Yuanlijian
- Eisai Co.
- Teva
- LIVZON
- Guangdong Huanan Pharma
- Bayer
- AbbVie
- Viatris
- Otsuka Pharmaceutical
- Nostrum Pharmaceuticals
- Endo International
- Astellas Pharma
- Amneal Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Gastric Mucosal Protective Drug Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Gastric Mucosal Protective Drug Market Size by Region (2021-2032)
- 1.4.1 Global Gastric Mucosal Protective Drug Market Size by Region (2021-2026)
- 1.4.2 Global Gastric Mucosal Protective Drug Market Size by Region (2027-2032)
- 1.5 Key Regions Gastric Mucosal Protective Drug Market Size (2021-2032)
- 1.5.1 North America Gastric Mucosal Protective Drug Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Gastric Mucosal Protective Drug Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Gastric Mucosal Protective Drug Market Size Growth Rate (2021-2032)
- 1.5.4 South America Gastric Mucosal Protective Drug Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Gastric Mucosal Protective Drug Market Size Growth Rate (2021-2032)
2 Gastric Mucosal Protective Drug Market by Type
- 2.1 Type Introduction
- 2.1.1 Rebamipide
- 2.1.2 Sucralfate
- 2.1.3 Bismuth Potassium Citrate
- 2.1.4 Other
- 2.2 Global Gastric Mucosal Protective Drug Market Size by Type
- 2.2.1 Global Gastric Mucosal Protective Drug Market Size Overview by Type (2021-2032)
- 2.2.2 Global Gastric Mucosal Protective Drug Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Gastric Mucosal Protective Drug Market Size Forecasted by Type (2027-2032)
- 2.3 Global Gastric Mucosal Protective Drug Market Size by Regions
- 2.3.1 North America Gastric Mucosal Protective Drug Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Gastric Mucosal Protective Drug Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Gastric Mucosal Protective Drug Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Gastric Mucosal Protective Drug Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Gastric Mucosal Protective Drug Market Size Breakdown by Type (2021-2026)
3 Gastric Mucosal Protective Drug Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Retail Pharmacy
- 3.1.3 Other
- 3.2 Global Gastric Mucosal Protective Drug Market Size by Application
- 3.2.1 Global Gastric Mucosal Protective Drug Market Size Overview by Application (2021-2032)
- 3.2.2 Global Gastric Mucosal Protective Drug Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Gastric Mucosal Protective Drug Market Size Forecasted by Application (2027-2032)
- 3.3 Global Gastric Mucosal Protective Drug Market Size by Regions
- 3.3.1 North America Gastric Mucosal Protective Drug Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Gastric Mucosal Protective Drug Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Gastric Mucosal Protective Drug Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Gastric Mucosal Protective Drug Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Gastric Mucosal Protective Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Gastric Mucosal Protective Drug Industry Trends
- 4.2 Gastric Mucosal Protective Drug Industry Drivers
- 4.3 Gastric Mucosal Protective Drug Industry Opportunities and Challenges
- 4.4 Gastric Mucosal Protective Drug Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Gastric Mucosal Protective Drug Revenue (2021-2026)
- 5.2 Global Gastric Mucosal Protective Drug Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Gastric Mucosal Protective Drug Key Company Headquarters & Area Served
- 5.4 Global Gastric Mucosal Protective Drug Company, Product Type & Application
- 5.5 Global Gastric Mucosal Protective Drug Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Gastric Mucosal Protective Drug Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Gastric Mucosal Protective Drug Players Market Share by Revenue in 2025
- 5.6.3 2025 Gastric Mucosal Protective Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Zhejaing Yuanlijian
- 6.1.1 Zhejaing Yuanlijian Company Information
- 6.1.2 Zhejaing Yuanlijian Business Overview
- 6.1.3 Zhejaing Yuanlijian Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Zhejaing Yuanlijian Gastric Mucosal Protective Drug Product Portfolio
- 6.1.5 Zhejaing Yuanlijian Recent Developments
- 6.2 Eisai Co.
- 6.2.1 Eisai Co. Company Information
- 6.2.2 Eisai Co. Business Overview
- 6.2.3 Eisai Co. Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Eisai Co. Gastric Mucosal Protective Drug Product Portfolio
- 6.2.5 Eisai Co. Recent Developments
- 6.3 Teva
- 6.3.1 Teva Company Information
- 6.3.2 Teva Business Overview
- 6.3.3 Teva Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Teva Gastric Mucosal Protective Drug Product Portfolio
- 6.3.5 Teva Recent Developments
- 6.4 LIVZON
- 6.4.1 LIVZON Company Information
- 6.4.2 LIVZON Business Overview
- 6.4.3 LIVZON Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 LIVZON Gastric Mucosal Protective Drug Product Portfolio
- 6.4.5 LIVZON Recent Developments
- 6.5 Guangdong Huanan Pharma
- 6.5.1 Guangdong Huanan Pharma Company Information
- 6.5.2 Guangdong Huanan Pharma Business Overview
- 6.5.3 Guangdong Huanan Pharma Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Guangdong Huanan Pharma Gastric Mucosal Protective Drug Product Portfolio
- 6.5.5 Guangdong Huanan Pharma Recent Developments
- 6.6 Bayer
- 6.6.1 Bayer Company Information
- 6.6.2 Bayer Business Overview
- 6.6.3 Bayer Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Bayer Gastric Mucosal Protective Drug Product Portfolio
- 6.6.5 Bayer Recent Developments
- 6.7 AbbVie
- 6.7.1 AbbVie Company Information
- 6.7.2 AbbVie Business Overview
- 6.7.3 AbbVie Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 AbbVie Gastric Mucosal Protective Drug Product Portfolio
- 6.7.5 AbbVie Recent Developments
- 6.8 Viatris
- 6.8.1 Viatris Company Information
- 6.8.2 Viatris Business Overview
- 6.8.3 Viatris Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Viatris Gastric Mucosal Protective Drug Product Portfolio
- 6.8.5 Viatris Recent Developments
- 6.9 Otsuka Pharmaceutical
- 6.9.1 Otsuka Pharmaceutical Company Information
- 6.9.2 Otsuka Pharmaceutical Business Overview
- 6.9.3 Otsuka Pharmaceutical Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Otsuka Pharmaceutical Gastric Mucosal Protective Drug Product Portfolio
- 6.9.5 Otsuka Pharmaceutical Recent Developments
- 6.10 Nostrum Pharmaceuticals
- 6.10.1 Nostrum Pharmaceuticals Company Information
- 6.10.2 Nostrum Pharmaceuticals Business Overview
- 6.10.3 Nostrum Pharmaceuticals Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Nostrum Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio
- 6.10.5 Nostrum Pharmaceuticals Recent Developments
- 6.11 Endo International
- 6.11.1 Endo International Company Information
- 6.11.2 Endo International Business Overview
- 6.11.3 Endo International Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Endo International Gastric Mucosal Protective Drug Product Portfolio
- 6.11.5 Endo International Recent Developments
- 6.12 Astellas Pharma
- 6.12.1 Astellas Pharma Company Information
- 6.12.2 Astellas Pharma Business Overview
- 6.12.3 Astellas Pharma Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Astellas Pharma Gastric Mucosal Protective Drug Product Portfolio
- 6.12.5 Astellas Pharma Recent Developments
- 6.13 Amneal Pharmaceuticals
- 6.13.1 Amneal Pharmaceuticals Company Information
- 6.13.2 Amneal Pharmaceuticals Business Overview
- 6.13.3 Amneal Pharmaceuticals Gastric Mucosal Protective Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Amneal Pharmaceuticals Gastric Mucosal Protective Drug Product Portfolio
- 6.13.5 Amneal Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Gastric Mucosal Protective Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Gastric Mucosal Protective Drug Market Size by Country (2021-2026)
- 7.3 North America Gastric Mucosal Protective Drug Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Gastric Mucosal Protective Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Gastric Mucosal Protective Drug Market Size by Country (2021-2026)
- 8.3 Europe Gastric Mucosal Protective Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Gastric Mucosal Protective Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Gastric Mucosal Protective Drug Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Gastric Mucosal Protective Drug Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Gastric Mucosal Protective Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Gastric Mucosal Protective Drug Market Size by Country (2021-2026)
- 10.3 South America Gastric Mucosal Protective Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Gastric Mucosal Protective Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Gastric Mucosal Protective Drug Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Gastric Mucosal Protective Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst